For which patients with resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
The initial results of IMpower010 were presented by Dr. @Dr. First Last at ASCO 2021. This study demonstrated that adjuvant atezolizumab following surgical resection and adjuvant platinum based chemotherapy improved disease free survival in stage II-IIIA NSCLC patients with tumors with PDL1 expressi...
There were several primary endpoints in IMpower010 that met statistical significance including disease free survival (DFS) in the PDL1 positive (≥1%) stage II-IIIA subgroup (DFS HR 0.66, 95% CI 0.50-0.88, p=0.0039) and all patients stage II-IIIA subgroup (DFS HR 0.79, 95% CI 0.64-0.96, p=0.020). Tho...
IMpower010 demonstrated a DFS benefit for patients with resected stage II-IIIA NSCLC expressing PD-L1 1% or greater (HR 0.66, 95% CI 0.50-0.88, p=0.00039). The secondary endpoint of DFS in patients with II-IIIA NSCLC high PD-L1 expression at 50% or more was met with an impressive HR of 0.43 (95% CI ...